Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 70010-134

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 70010-134). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Granules Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Esome-20mg-30s (Esome 20mg 30s)

Esome-20mg-30s (Esome 20mg 30s)
Label for Esomeprazole Magnesium delayed-release capsules, USP 20 mg. The label indicates a package of 30 capsules, prescription only, manufactured by Granules India Limited and labeled for Granules Pharmaceuticals Inc., Chantilly, VA. It includes storage instructions and a barcode.*
FDA Label Image

Esome-40mg-30s (Esome 40mg 30s)

Esome-40mg-30s (Esome 40mg 30s)
Label for Esomeprazole Magnesium Delayed-Release Capsules, USP 40 mg by Granules Pharmaceuticals Inc. The package contains 30 capsules for oral use. Each delayed-release capsule contains 40 mg esomeprazole equivalent to 44.5 mg esomeprazole magnesium trihydrate USP. Manufactured by Granules India Limited, Hyderabad, India. Barcode and storage information included.*
FDA Label Image

Esome-structure (Esome Structure)

Esome-structure (Esome Structure)
Chemical structure of esomeprazole magnesium showing the molecular arrangement including methoxy groups, nitrogen atoms, sulfoxide, and magnesium ion coordination with 3 water molecules.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph showing the percentage of patients who maintained a condition over a 6-month period for different treatments: Esomeprazole Magnesium 40 mg, 20 mg, 10 mg, and Placebo. The vertical axis is labeled 'Percent Maintained,' and the horizontal axis shows months with scheduled visits marked. Lines for 40 mg and 20 mg doses show higher maintenance percentages compared to lower dose and placebo over time.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line chart illustrating the percent maintained response over a six-month period for esomeprazole magnesium capsules at 40 mg, 20 mg, 10 mg doses, and a placebo. The x-axis represents months with scheduled visits, and the y-axis shows percent maintained. The 40 mg and 20 mg dosages show higher maintenance compared to 10 mg and placebo groups.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph comparing the percent of patients symptom-free over 28 diary days for three groups: Esomeprazole magnesium delayed-release capsules 40 mg, 20 mg, and placebo. The 40 mg group shows the highest symptom-free percentage, followed by 20 mg, with placebo the lowest throughout the period.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
Line chart showing the percentage of patients symptom-free over 28 diary days. The graph compares Esomeprazole Magnesium delayed-release capsules at 20 mg and 40 mg doses versus placebo, illustrating higher symptom-free percentages for treatment groups across the study period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.